首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   353507篇
  免费   55999篇
  国内免费   887篇
耳鼻咽喉   5535篇
儿科学   12840篇
妇产科学   6717篇
基础医学   52319篇
口腔科学   15517篇
临床医学   31835篇
内科学   86874篇
皮肤病学   14452篇
神经病学   36088篇
特种医学   9956篇
外国民族医学   27篇
外科学   49316篇
综合类   2190篇
现状与发展   1篇
一般理论   115篇
预防医学   32223篇
眼科学   7087篇
药学   22961篇
中国医学   2265篇
肿瘤学   22075篇
  2023年   1729篇
  2022年   3708篇
  2021年   8549篇
  2020年   8689篇
  2019年   16451篇
  2018年   18049篇
  2017年   16335篇
  2016年   16745篇
  2015年   17400篇
  2014年   20048篇
  2013年   23627篇
  2012年   22874篇
  2011年   23816篇
  2010年   18897篇
  2009年   14032篇
  2008年   17425篇
  2007年   17162篇
  2006年   16180篇
  2005年   16063篇
  2004年   15004篇
  2003年   13932篇
  2002年   11675篇
  2001年   8355篇
  2000年   8634篇
  1999年   6795篇
  1998年   2419篇
  1997年   2006篇
  1996年   1886篇
  1995年   1629篇
  1994年   1562篇
  1993年   1372篇
  1992年   3359篇
  1991年   3179篇
  1990年   2890篇
  1989年   2794篇
  1988年   2571篇
  1987年   2358篇
  1986年   2182篇
  1985年   2094篇
  1984年   1531篇
  1983年   1257篇
  1982年   806篇
  1981年   755篇
  1980年   669篇
  1979年   1130篇
  1978年   803篇
  1977年   614篇
  1975年   669篇
  1974年   721篇
  1973年   719篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
2.
3.
4.
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status...  相似文献   
5.
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to...  相似文献   
6.
7.
8.
9.
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm.  相似文献   
10.
We review the spectrum of cutaneous disorders associated with inflammatory and neoplastic plasmacytic pathology. Because plasma cells are derived from B‐lymphocytes our overview includes discussion of certain lymphoplasmacytic proliferations. It is structured along histopathological lines, addressing conditions characterized by (a) cutaneous plasma cell infiltrates, (b) deposits of plasma cell products or their derivatives in the skin and (c) miscellaneous, poorly understood cutaneous complications of plasmacytic disorders. Lesions arising primarily in the skin and those due to cutaneous involvement by multisystem disorders are addressed. The range includes a spectrum of tumefactive and circulatory manifestations. We highlight key clinical and pathological features of the different conditions and outline recent advances in our understanding of these entities. By emphasizing the dermatopathological characteristics of this spectrum of disorders we hope to hone the diagnostic accuracy of practitioners in the field.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号